City

Houston (1)

Tucson (1)

Condition

Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7 (2)

Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 (2)

Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 (2)

CDKN2A-p16 Positive (1)

Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma (1)

Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7 (1)

Overall Status

Completed (1)

Recruiting (1)

Sign in for free

Phase

phase 1 (1)

phase 2 (1)

Sponsor

M.D. Anderson Cancer Center (1)

University of Arizona (1)

Collaborator

National Cancer Institute (NCI) (2)

Intervention

alpelisib (1)

durvalumab (1)

laboratory biomarker analysis (1)

pharmacodynamic study (1)

therapeutic conventional surgery (1)

tremelimumab (1)

Study Documents

Intervention Type

biological (1)

drug (1)

other (1)

procedure (1)

Funder Type

Other (2)

Study Type

Interventional (2)

stage ii oropharyngeal squamous cell carcinoma ajcc v6 and v7

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

CDKN2A-p16 Positive, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell

Recruiting

CDKN2A-p16 Positive
+5 more

Alpelisib
+3 more

Tucson, Arizona

The University of Arizona Medical Center-University Campus

Mar 7, 2022

Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage

Completed

Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7
+2 more

Durvalumab
Tremelimumab

Houston, Texas

M D Anderson Cancer Center

Mar 16, 2021